Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Daratumumab/erythropoietin/rituximab

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Longval T. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible Pure Red Cell aplasia after allogenic HSCT: report from SFGM-TC. Swiss Medical Weekly 153 (Suppl.): 22S abstr. 214, No. 11, Jan 2023. Available from: URL: https://dx.doi.org/10.57187/s.3469 [abstract] Longval T. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible Pure Red Cell aplasia after allogenic HSCT: report from SFGM-TC. Swiss Medical Weekly 153 (Suppl.): 22S abstr. 214, No. 11, Jan 2023. Available from: URL: https://dx.doi.org/10.57187/s.3469 [abstract]
Metadaten
Titel
Daratumumab/erythropoietin/rituximab
Lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56795-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Antineoplastics

Case report

Prednisolone

Case report

Lenvatinib